Abstract:Background and purposeNon-small cell lung cancer (NSCLC) is a major pathological type of lung cancer and accounts for more than 80% of all cases. In healthcare management, it is challenging to understand the mechanism of NSCLC due to diverse spectra and the limited number of reported data. Selaginella tamariscina is an evergreen perennial plant, hermaphrodite, and used to treat numerous diseases, including NSCLC. In vitro research revealed the therapeutic importance of S. tamariscina in contrast to NSCLC, but the molecular mechanism is still unclear. In the present study, a network pharmacology technique was employed to uncover the active ingredients, their potential targets, and signaling pathways in S. tamariscina for the treatment of NSCLC.MethodsPutative ingredients of S. tamariscina and significant genes of NSCLC were retrieved from the public database after screening. The overlapped targets among S. tamariscina related compounds and NSCLC were predicted using Venn plot. Following that, a compound-target-disease network was constructed using Cytoscape to decipher the mechanism of S. tamariscina for NSCLC. KEGG pathway and GO enrichment analysis were performed to investigate the molecular mechanisms and pathways related to S. tamariscina for NSCLC treatments. Lastly, molecular docking and molecular dynamic simulation analysis were performed to validate the interaction that exists between compounds and target proteins.ResultsThe findings of the current analysis explored the compound–target–pathway network and figured out that Hinokiflavone, Heveaflavone, Neocryptomerin, Isocryptomerin, Apigenin, Sotetsuflavone, and Cryptomerin B decisively contributed to the development of NSCLC by affecting AKT1, EGFR, VEGFA, and GCK3B genes. Later, molecular docking and simulation analysis was conducted to validate the successful activity of the active compounds against potential targets. Lastly, it is concluded that predicted multi-target compounds of S. tamariscina will help in improving the body's sensitivity to NSCLC by regulating the expression of AKT1, EGFR, VEGFA, and GCK3B, which may act as potential therapeutic targets of NSCLC.ConclusionIntegrated network pharmacology and docking analysis revealed that S. tamariscina exerted a promising preventive effect on NSCLC by acting on diabetes-associated signaling pathways. The current findings propose that AKT1, VEGFA, EGFR, and GSK3B genes are promising and viable therapeutic targets to reduce the incidence of NSCLC, thereby exerting potential therapeutic effects in NSCLC. This approach introduces a groundwork for further research on the protective mechanisms of S. tamariscina for NSCLC and applications of network pharmacology in drug discovery.

Valencene as a novel potential downregulator of THRB in NSCLC: network pharmacology, molecular docking, molecular dynamics simulation, ADMET analysis, and in vitro analysis

Biological evaluation of levofloxacin and its thionated derivatives: antioxidant activity, aldehyde dehydrogenase enzyme inhibition, and cytotoxicity on A549 cell line

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

Valtrate antagonizes malignant phenotypes of lung cancer cells by reducing SLC7A11

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Vinorelbine Alters lncRNA Expression in Association with EGFR Mutational Status and Potentiates Tumor Progression Depending on NSCLC Cell Lines’ Genetic Profile

Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions

S-(N,N-diethyldithiocarbamoyl)-N-acetyl-l-cysteine for the treatment of non-small cell lung cancer through regulating NF-κB signalling pathway without neurotoxicity

Impact of Nordihydroguaiaretic Acid on Proliferation, Energy Metabolism, and Chemosensitization in Non-Small-Cell Lung Cancer (NSCLC) Cell Lines

Exploring natural compounds for the management of non-small cell lung cancer

To Reveal the Potential Mechanism of Quercetin against NSCLC Based on Network Pharmacology and Experimental Validation

Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail)-Induced Apoptosis in NSCLC Cells

Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach

Novel Retinoid-Related Molecules As Apoptosis Inducers and Effectve Inhibitors of Human Lung Cancer Cells in Vivo

Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-κB pathways with novel theanine derivatives.

High throughput virtual screening and validation of Plant-Based EGFR L858R kinase inhibitors against Non-Small cell lung Cancer: An integrated approach Utilizing GC-MS, network Pharmacology, Docking, and molecular dynamics

Integrated network pharmacology and in-silico approaches to decipher the pharmacological mechanism of Selaginella tamariscina in the treatment of non-small cell lung cancer

Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer

Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis

Selective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy

Phenolic diterpenes from Rosemary supercritical extract inhibit non-small cell lung cancer lipid metabolism and synergise with therapeutic drugs in the clinic